Efficacy and Safety Profile of Treatment with Etoricoxib 120 mg Once Daily Compared with Indomethacin 50 mg Three Times Daily in Acute Gout: A Randomized Controlled Trial

Arthritis and Rheumatism

Volumn 50, Issue 2, 2004, Pages 598-606

  Rubin, Bernard R ^a   Burton, Robert ^b   Navarra, Sandra ^c   Antigua, Joseph ^d   Londoño, John ^e   Pryhuber, Keith G ^f   Lund, Margaret ^g   Chen, Erluo ^g   Najarian, Daryl K ^g   Petruschke, Richard A ^g   Ozturk, Zafer E ^g   Geba, Gregory P ^g  

^a UNIVERSITY OF NORTH TEXAS   (United States)

^b Qual Res for Medical Advancement   (United States)

^c UNIVERSITY OF SANTO TOMAS HOSPITAL   (Philippines)

^d Chong Hua Hospital   (Philippines)

^e HOSPITAL MILITAR CENTRAL   (Colombia)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETORICOXIB; INDOMETACIN;

ACUTE DISEASE; ADULT; ADVERSE DRUG REACTION; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; GOUT; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; UREMIA;

ADMINISTRATION, ORAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; INDOMETHACIN; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PYRIDINES; SULFONES; TREATMENT OUTCOME;

EID: 10744230643     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20007     Document Type: Article

References (40)

1. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician 1999;59:925-34.
2. Schumacher HR. Crystal-induced arthritis: an overview. Am J Med 1996;100 Suppl 2A:46S-52S.
3. Fam AG. Gout in the elderly: clinical presentation and treatment. Drugs Aging 1998;13:229-43.
4. Landis RD, Haskard DO. Pathogenesis of crystal-induced inflammation. Curr Rheumatol Rep 2001;3:36-41.
5. Reginato A, Paul H, Schumacher HR. Crystal-induced arthritis. Arch Phys Med Rehabil 1982;63:401-8.
6. Wyngaarden JB. Gout. Adv Metab Disord 1965;2:1-78.
7. Terkeltaub RA, Ginsberg MH. The inflammatory reaction to crystals. Rheum Dis Clin North Am 1988;14:353-64.
8. Van Doornum S, Ryan PF. Clinical manifestations of gout and their management. Med J Aust 2000;172:493-7.
9. Buckley TJ. Radiologic features of gout. Am Fam Physician 1996;54:1232-8.
10. Pouliot M, James MJ, McColl SR, Naccache PH, Cleland LG. Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 1998;91:1769-76.
11. Wortmann RL. Effective management of gout: an analogy. Am J Med 1998;105:513-4.
12. Pittman JR, Bross MH. Diagnosis and management of gout. Am Fam Physician 1999;59:1799-806, 1810.
13. Emmerson BT. The management of gout. N Engl J Med 1996;334:445-51.
14. Levy M, Spino M, Read SE. Colchicine: a state-of-the-art review. Pharmacotherapy 1991;11:196-211.
15. Bjorkman DJ. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am J Med 1999;107:3S-8S.
16. Raskin JB. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 1999;106:3S-12S.
17. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-99.
18. Cappell MS, Schein JR. Diagnosis and treatment of nonsteroidal anti-inflammatory drug-associated upper gastrointestinal toxicity. Gastroenterol Clin North Am 2000;29:97-124, vi.
19. McCarthy DM. Comparative toxicity of nonsteroidal anti-inflammatory drugs. Am J Med 1999;107:37S-46S.
20. Jouzeau JY, Terlain B, Abid A, Nedelec E, Netter P. Cyclooxygenase isoenzymes: how recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997;53:563-82.
21. Donnelly MT, Hawkey CJ. COX-II inhibitors-a new generation of safer NSAIDs? Aliment Pharmacol Ther 1997;11:227-36.
22. Peura DA. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. Cleve Clin J Med 2002;69 Suppl 1:SI31-9.
23. Scheiman JM. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med 2002;69 Suppl 1:SI40-6.
24. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, David B, et al, for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
25. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296:558-66.
26. Schnitzer TJ, Hochberg MC. COX-2-selective inhibitors in the treatment of arthritis. Cleve Clin J Med 2002;69 Suppl 1:SI20-30.
27. Leung AT, Malmstrom K, Gallacher AE, Sarembock B, Poor G, Beaulieu A, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002;18:49-58.
28. Schumacher HR Jr, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002;324:1488-92.
29. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü T-F. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
30. Terkeltaub RA, Edwards NL, Pratt PW, Ball GV. Gout. In: Klippel JH, Weyand CM, Wortmann RL, editors. Primer on the rheumatic diseases. 11th ed. Atlanta: Arthritis Foundation; 1997. pp 230-45.
31. Altman RD, Honig S, Levin JM, Lightfoot RW. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double-blind comparative study. J Rheumatol 1988;15:1422-6.
32. Bellamy N, Downie WW, Buchanan WW. Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of nonsteroidal anti-inflammatory drugs. Br J Clin Pharmacol 1987;24:33-6.
33. Smyth CJ. Indomethacin-its rightful place in treatment. Ann Intern Med 1970;72:430-2.
34. Karachalios GN. Treatment of acute gouty arthritis with piroxicam. Clin Exp Rheumatol 1985;3:63-5.
35. Willkens RF, Case JB, Huix FJ. The treatment of acute gout with naproxen. J Clin Pharmacol 1975;15:363-6.
36. Shrestha M, Morgan DL, Moreden JM, Singh R, Nelson M, Hayes JE. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995;26:682-6.
37. Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac (Lodine) compared with naproxen in patients with acute gout. Curr Med Res Opin 1991;12:423-9.
38. Currie WJ. The gout patient in general practice. Rheumatol Rehabil 1978;17:205-17.
39. Cochrane DJ, Jarvis B, Keating GM. Etoricoxib. Drugs 2002;62:2637-51.
40. Stichtenoth DO, Frolich JC. The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs 2003;63:33-45.